Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M964Revenue $M14.2Net Margin (%)-730.7Z-Score13.3
Enterprise Value $M686EPS $-3.3Operating Margin %-731.8F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-458.9Higher ROA y-yY
Price/Book3.210-y EBITDA Growth Rate %-9.1Quick Ratio10.4Cash flow > EarningsY
Price/Sales57.55-y EBITDA Growth Rate %25.2Current Ratio10.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-40.6Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-50.8Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M40.9ROI % (ttm)-300.9Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-06-30 Add0.14%$22.18 - $38.91
$ 23.56-26%Add 2620%680,000
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
$ 23.56-7%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
$ 23.56-20%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
$ 23.56-39%Add 56.28%665,274
SRPTAndreas Halvorsen 2013-09-30 Sold Out -0.14%$30.906 - $47.97
$ 23.56-39%Sold Out0
SRPTAndreas Halvorsen 2013-03-31 Buy 0.15%$23.97 - $36.95
$ 23.56-18%New holding, 690731 sh.690,731
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
$ 23.56-18%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
$ 23.56-12%Add 184.13%226,429
SRPTJean-Marie Eveillard 2012-03-31 Sold Out $4.5 - $9.6
$ 23.56289%Sold Out0
SRPTJean-Marie Eveillard 2011-12-31 Reduce$3.24 - $6.54
$ 23.56368%Reduce -83.33%50,000
SRPTJean-Marie Eveillard 2011-09-30 Add$6.3 - $9.9
$ 23.56198%Add 50%300,000
SRPTJean-Marie Eveillard 2011-06-30 Buy $8.1 - $11.22
$ 23.56144%New holding, 200000 sh.200,000
SRPTGeorge Soros 2006-03-31 Buy 0.08%$24.54 - $50.45
$ 23.56-43%New holding, 308100 sh.308,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SRPT George Soros 2014-06-30680,0001.660.15+2620%
Premium Most recent portfolio changes are included for Premium Members only!

SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.9565.16view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.5683.44view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-37.8view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-34.11view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-29.5view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.1-25.92view
Price Ben GilDirector 2013-08-19Buy500$31.18-26.11view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.5-40.16view
CHASE ANTHONY RDirector 2012-11-28Sell10,000$29.46-21.79view
CHASE ANTHONY RDirector 2012-11-14Sell10,000$25.7-10.35view

Press Releases about SRPT :

    Quarterly/Annual Reports about SRPT:

    News about srpt:

    Articles On GuruFocus.com
    Ebola: Is The Cure Out There? Oct 14 2014 
    Insiders Are Buying Fate Therapeutics Oct 09 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Feb 16 2013 

    More From Our Partners
    Stomach-Churning Ride for Ebola Stocks Oct 17 2014 - FOXBUSINESS

    More From Other Websites
    Ebola vaccine could be ready in 3 months: CEO Oct 21 2014
    EU offers benefits of "orphan" disease status to Ebola drugs Oct 20 2014
    A Promising Experimental Ebola Drug Goes Overlooked Oct 20 2014
    Sarepta Therapeutics Shares Up On Ebola Drug Safety Study Oct 17 2014
    Ahead of the Bell: Sarepta Therapeutics climbs Oct 17 2014
    Ahead of the Bell: Sarepta Therapeutics climbs Oct 17 2014
    Sarepta Is Surging After Good News For Its Ebola Treatment Oct 17 2014
    [$$] Sarepta's Ebola Drug Showed No Ill Effects in Study Oct 16 2014
    Sarepta says its Ebola drug has no ill effects Oct 16 2014
    Sarepta Therapeutics Announces Publication of Ebola and Marburg Phase I Clinical Study Results in... Oct 16 2014
    After-hours buzz: Google, SanDisk, Xilinx & more Oct 16 2014
    Sarepta says it sees no side effects from Ebola drug Oct 16 2014
    Sarepta Therapeutics Announces Publication of Ebola and Marburg Phase I Clinical Study Results in... Oct 16 2014
    Volatility at its finest Oct 15 2014
    [video] Funding pandemic preparedness Oct 13 2014
    [video] CDC: Won't block West African flights Oct 13 2014
    Sarepta Drug Could Benefit From Duchenne Muscular Dystrophy Patient Study Oct 13 2014
    [video] Questioning Ebola protocols Oct 13 2014
    Questioning Ebola protocols Oct 13 2014
    [video] US nurses properly trained for Ebola? Oct 13 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial